Clinical companies

Syncona’s clinical companies have screened and enrolled the first patient into a clinical trial and are scaling towards late-stage development.

Syncona’s clinical portfolio comprises companies with the potential to treat patients across a range of conditions.

Key facts

Unless stated all financials at 30 September 2026

£347m

Value of clinical portfolio

14

Number of clinical trials

12

Portfolio Company Board seats

Our clinical stage portfolio companies